<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dornase alfa: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dornase alfa: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dornase alfa: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12394" href="/d/html/12394.html" rel="external">see "Dornase alfa: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13249" href="/d/html/13249.html" rel="external">see "Dornase alfa: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F161836"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pulmozyme</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866637"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Pulmozyme</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F161871"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Enzyme;</li>
<li>
                        Mucolytic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F161839"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df85d498-37b3-4d24-95e1-d4a9ea8cb8c0">Cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis:</b>
<b>Inhalation:</b> 2.5 mg once daily through selected jet nebulizers in conjunction with an air compressor system (Durable Sidestream, Hudson T Up-draft II, Marquest Acorn II, PARIBABY, or PARI LC Plus) or eRapid Nebulizer System. Some patients may benefit from twice daily administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Patients unable to inhale or exhale orally throughout the entire treatment period may use Pari-Baby nebulizer.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef220066-a0a1-41cf-95cc-8551f5caff94">Parapneumonic effusions, complicated and empyema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parapneumonic effusions, complicated and empyema (adjunctive agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>:</b> Consider in combination with thrombolytic in patients who do not sufficiently respond to conventional therapy (eg, chest tube drainage, antibiotics) and/or who are not surgical candidates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25296241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25296241'])">Ref</a></span>). Optimal regimen and doses have not been identified; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intrapleural:</b> 5 mg once or twice daily for 3 days; used sequentially or concurrently with intrapleural alteplase. For sequential dosing, administer alteplase first, then administer dornase alfa and dwell for ~1 hour and drain for ~1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32746902','lexi-content-ref-25296241','lexi-content-ref-21830966']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32746902','lexi-content-ref-25296241','lexi-content-ref-21830966'])">Ref</a></span>). For concurrent dosing, administer dornase alfa and alteplase via 2 separate syringes, followed by a 10 to 60 mL saline flush; dwell for ~1 to 2 hours then drain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32746902','lexi-content-ref-27333122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32746902','lexi-content-ref-27333122'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990226"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987533"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F161840"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F161855"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13249" href="/d/html/13249.html" rel="external">see "Dornase alfa: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="08c54461-154f-4519-944e-52f824c441e2">Cystic fibrosis, acute exacerbations and chronic use</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, </b>
<b>acute exacerbations and chronic use:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants (limited data available in &lt;3 months of age), Children, and Adolescents: Inhalation: Nebulization: 2.5 mg once daily through eRapid nebulizer or selected jet nebulizers in conjunction with an approved air compressor system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15463871','lexi-content-ref-19914445','lexi-content-ref-27009033','lexi-content-ref-17726701','lexi-content-ref-11340684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15463871','lexi-content-ref-19914445','lexi-content-ref-27009033','lexi-content-ref-17726701','lexi-content-ref-11340684'])">Ref</a></span>). Some older patients (generally, those &gt;21 years of age) or patients with baseline forced vital capacity &gt;85% may require twice-daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6abb443-1858-42b0-a6ba-ebfa9b299c6b">Rhinosinusitis, chronic; secondary to cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, chronic; secondary to cystic fibrosis</b>: Limited data available: Children ≥5 years and Adolescents: Inhalation: Intranasal: 2.5 mg once daily nebulized intranasal with the Pari Sinus; dosing based on double-blind, placebo-controlled cross-over trial in 23 subjects (age range: 5 to 67 years) which showed improvement of primary nasal symptoms compared to placebo (isotonic saline); treatments were well tolerated; nasal bleeding was reported in 2 patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24594542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24594542'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51107936"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51107937"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F161815"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse events were similar in children using the PARI BABY nebulizer (facemask as opposed to mouthpiece) with the addition of cough.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (18% to 25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Voice disorder (12% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (3% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (PARI-BABY nebulizer facemask: children 3 months to &lt;5 years: 45%; children 5 to ≤10 years: 30%), pharyngitis (32% to 40%), rhinitis (30%; in patients with FVC: &lt;40%), decrease in forced vital capacity (≥10% decrease of predicted: 22%; in patients with FVC: &lt;40%), dyspnea (17%; in patients with FVC: &lt;40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (32% in patients with FVC &lt;40%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (to dornase alfa: 2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Laryngitis (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Headache, urticaria</p></div>
<div class="block coi drugH1Div" id="F161826"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to dornase alfa, Chinese hamster ovary cell products, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F161812"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Decreased pulmonary function: In patients with pulmonary function &lt;40% of normal, dornase alfa does not significantly reduce the risk of respiratory infections that require parenteral antibiotics.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878430"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some adverse effects were reported more frequently in infants and children &lt;5 years of age than older children (5 to 10 years of age) including cough (45% vs 30%), rhinitis (35% vs 27%), and rash (6% vs 0%).</p></div>
<div class="block foc drugH1Div" id="F161821"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pulmozyme: 2.5 mg/2.5 mL (2.5 mL)</p></div>
<div class="block geq drugH1Div" id="F161808"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F161828"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Pulmozyme Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/2.5 mL (per mL): $62.34</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866638"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pulmozyme: 2.5 mg/2.5 mL (2.5 mL)</p></div>
<div class="block adm drugH1Div" id="F161823"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nebulization:</b> Administer via the eRapid Nebulizer System or via a jet nebulizer (Durable Sidestream, Hudson T Up-draft II, Marquest Acorn II, PARIBABY, or PARI LC Plus) connected to an approved air compressor (Pulmo-Aide, PariProneb, Mobilaire or PortaNeb) with air flow of ~3.5 to 9 L/minute at ~20 to 45 psi pressure and equipped with a face mask or mouthpiece. Prior to use, squeeze each ampul to check for leaks. Once ampul is opened, the entire contents must be used or discarded. Do not dilute or mix with any other drugs in the nebulizer, this may inactivate the drug. When administered with the eRapid Nebulizer System, replace handset after 90 uses to ensure delivery of appropriate dose. Follow the manufacturer's instructions on use and maintenance of the equipment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrapleural: </b>
<i>Parapneumonic effusions, complicated and empyema (off-label use): </i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sequential administration</i>: For sequential administration of alteplase and dornase alfa, dilute each dose in 30 to 50 mL NS or sterile waterr; administer alteplase first and let dwell, then drain; after alteplase drain, administer dornase alfa, followed by a saline flush (eg, 10 to 25 mL); dwell for ~1 hour and drain for ~1 hour. Stability of dornase alfa diluted in NS or sterile water has not been formally evaluated; use immediately after preparation. Instill dose into chest tube and clamp drain. After ~1 hour dwell time, release clamp and connect chest tube to continuous suction to drain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32746902','lexi-content-ref-25296241','lexi-content-ref-21830966']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32746902','lexi-content-ref-25296241','lexi-content-ref-21830966'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Concurrent administration:</i> For concurrent administration of alteplase and dornase alfa, using separate syringes, dilute dornase alfa dose in 30 to 50 mL NS or sterile water. Stability of dornase alfa diluted in NS or sterile water has not been formally evaluated; use immediately after preparation. Instill alteplase and dornase alfa into chest tube, one immediately after the other, followed by a 10 to 60 mL NS flush. Clamp drain for ~1 to 2 hours, then drain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32746902','lexi-content-ref-27333122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32746902','lexi-content-ref-27333122'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612598"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Inhalation:</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization: Should not be diluted or mixed with any other drugs in the nebulizer per the manufacturer's labeling; this may inactivate the drug. Dilution in NS (1 to 5 mL) has been reported in neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22366825','lexi-content-ref-22124516','lexi-content-ref-23915544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22366825','lexi-content-ref-22124516','lexi-content-ref-23915544'])">Ref</a></span>). Administer through eRapid Nebulizer system or select jet nebulizers (eg, Hudson T Up-Draft II, Marquest Acorn II, Pari LC Plus, Pari Baby, Durable Sidestream) in conjunction with an air compressor system (eg, Pulmo-Aide Pari-Proneb, Mobilaire, Porta-Neb).</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: Nebulize for 4 minutes per nostril using Pari Sinus compressor and Pari LC Sprint Star (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24594542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24594542'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F161822"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Cystic fibrosis:</b> Management of cystic fibrosis patients, in conjunction with standard therapies, to improve pulmonary function; reduce the risk of respiratory tract infections requiring parenteral antibiotics in patients with a forced vital capacity (FVC) ≥40% of predicted.</p></div>
<div class="block off-label drugH1Div" id="F25474999"><span class="drugH1">Use: Off-Label: Adult</span><p>Parapneumonic effusions, complicated and empyema</p></div>
<div class="block cyt drugH1Div" id="F13299229"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6219980"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F5131960"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F5131961"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Measurable amounts would not be expected in breast milk following inhalation; however, it is not known if dornase alfa is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>
<div class="block pha drugH1Div" id="F161811"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The hallmark of cystic fibrosis lung disease is the presence of abundant, purulent airway secretions composed primarily of highly polymerized DNA. The principal source of this DNA is the nuclei of degenerating neutrophils, which is present in large concentrations in infected lung secretions. The presence of this DNA produces a viscous mucous that may contribute to the decreased mucociliary transport and persistent infections that are commonly seen in this population. Dornase alfa is a deoxyribonuclease (DNA) enzyme produced by recombinant gene technology. Dornase selectively cleaves DNA, thus reducing mucous viscosity and as a result, airflow in the lung is improved and the risk of bacterial infection may be decreased.</p></div>
<div class="block phk drugH1Div" id="F161825"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Nebulization: Enzyme levels are measured in sputum in ~15 minutes and decline rapidly thereafter </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Sputum concentrations decline within 2 hours of inhalation</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F161829"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Pulmozyme</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Tigerase</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-7650767">
<a name="7650767"></a>Albertson TE, Walby WF, Allen RP, et al. The Pharmacology and Toxicology of Three New Biologic Agents Used in Pulmonary Medicine. <i>J Toxicol Clin Toxicol</i>. 1995;33(5):427-438.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/7650767/pubmed" id="7650767" target="_blank">7650767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22114907">
<a name="22114907"></a>Altunhan H, Annagür A, Pekcan S, Ors R, Koç H. Comparing the efficacy of nebulizer recombinant human DNase and hypertonic saline as monotherapy and combined treatment in the treatment of persistent atelectasis in mechanically ventilated newborns. <i>Pediatr Int</i>. 2012;54(1):131-136. doi:10.1111/j.1442-200X.2011.03519.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/22114907/pubmed" id="22114907" target="_blank">22114907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15463871">
<a name="15463871"></a>Berge MT, Wiel Ev, Tiddens HA, Merkus PJ, Hop WC, de Jongste JC. DNase in stable cystic fibrosis infants: a pilot study. <i>J Cyst Fibros</i>. 2003;2(4):183-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/15463871/pubmed" id="15463871" target="_blank">15463871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19914445">
<a name="19914445"></a>Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. <i>J Pediatr</i>. 2009;155(6 Suppl):S73-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/19914445/pubmed" id="19914445" target="_blank">19914445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20696693">
<a name="20696693"></a>Davies HE, Davies RJ, Davies CW; BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. <i>Thorax</i>. 2010;65(suppl 2):ii41-ii53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/20696693/pubmed" id="20696693" target="_blank">20696693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20831650">
<a name="20831650"></a>Dilmen U, Karagol BS, Oguz SS. Nebulized hypertonic saline and recombinant human DNase in the treatment of pulmonary atelectasis in newborns. <i>Pediatr Int</i>. 2011;53(3):328-331. doi:10.1111/j.1442-200X.2010.03245.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/20831650/pubmed" id="20831650" target="_blank">20831650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17436388">
<a name="17436388"></a>Erdeve O, Uras N, Atasay B, Arsan S. Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series. <i>Croat Med J</i>. 2007;48(2):234-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/17436388/pubmed" id="17436388" target="_blank">17436388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22366825">
<a name="22366825"></a>Fedakar A, Aydogdu C, Fedakar A, Ugurlucan M, Bolu S, Iskender M. Safety of recombinant human deoxyribonuclease as a rescue treatment for persistent atelectasis in newborns. <i>Ann Saudi Med</i>. 2012;32(2):131-136. doi:10.5144/0256-4947.2012.131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/22366825/pubmed" id="22366825" target="_blank">22366825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7503821">
<a name="7503821"></a>Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients With Cystic Fibrosis. <i>N Engl J Med</i>. 1994;331(10):637-642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/7503821/pubmed" id="7503821" target="_blank">7503821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20653362">
<a name="20653362"></a>Hamblin SE, Furmanek DL. Intrapleural tissue plasminogen activator for the treatment of parapneumonic effusion. <i>Pharmacotherapy</i>. 2010;30(8):855-862.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/20653362/pubmed" id="20653362" target="_blank">20653362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1538726">
<a name="1538726"></a>Hubbard RC, McElvaney NG, Birrer P, et al. A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis. <i>N Engl J Med</i>. 1992;326(12):812-815.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/1538726/pubmed" id="1538726" target="_blank">1538726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32746902">
<a name="32746902"></a>Jiang C, Xie M, Cervellione K, Thurm C. Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study. <i>BMC Res Notes.</i> 2020;13(1):368. doi:10.1186/s13104-020-05210-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/32746902/pubmed" id="32746902" target="_blank">32746902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27009033">
<a name="27009033"></a>Lahiri T, Hempstead SE, Brady C, et al. Clinical Practice Guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. <i>Pediatrics</i>. 2016;137(4).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/27009033/pubmed" id="27009033" target="_blank">27009033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22124516">
<a name="22124516"></a>MacKinnon R, Wheeler KI, Sokol J. Endotracheal DNase for atelectasis in ventilated neonates. <i>J Perinatol</i>. 2011;31(12):799-801. doi:10.1038/jp.2011.38<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/22124516/pubmed" id="22124516" target="_blank">22124516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24594542">
<a name="24594542"></a>Mainz JG, Schien C, Schiller I, et al. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. <i>J Cyst Fibros</i>. 2014;13(4):461-470.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/24594542/pubmed" id="24594542" target="_blank">24594542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27333122">
<a name="27333122"></a>Majid A, Kheir F, Folch A, et al. Concurrent intrapleural instillation of tissue plasminogen activator and DNase for pleural infection. A single-center experience. <i>Ann Am Thorac Soc</i>. 2016;13(9):1512-1518. doi: 10.1513/AnnalsATS.201602-127OC.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/27333122/pubmed" id="27333122" target="_blank">27333122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17726701">
<a name="17726701"></a>McKenzie SG, Chowdhury S, Strandvik B, et al. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. <i>Pediatr Pulmonol</i>. 2007;42(10):928-937.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/17726701/pubmed" id="17726701" target="_blank">17726701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23540878">
<a name="23540878"></a>Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/23540878/pubmed" id="23540878" target="_blank">23540878</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mueller GA, Rubins G, Wessel D, et al. Effects of Dornase Alfa on Pulmonary Function Tests in Infants with Cystic Fibrosis. <i>Am J Respir Crit Care Med</i>. 1996;153:A70.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11340684">
<a name="11340684"></a>Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. <i>Pediatr Pulmonol</i>. 2001;31(5):377-382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/11340684/pubmed" id="11340684" target="_blank">11340684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23915544">
<a name="23915544"></a>Ozturk E, Tanidir IC, Haydin S, Onan IS, Odemis E, Bakir I. The use of dornase alpha for post-operative pulmonary atelectasis after congenital heart surgery. <i>Cardiol Young</i>. 2014;24(5):807-812. doi:10.1017/S1047951113001078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/23915544/pubmed" id="23915544" target="_blank">23915544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25296241">
<a name="25296241"></a>Piccolo F, Pitman N, Bhatnagar R, et al. Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery. <i>Ann Am Thorac Soc</i>. 2014;11(9):1419-1425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/25296241/pubmed" id="25296241" target="_blank">25296241</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pulmozyme (dornase alfa) [prescribing information]. South San Francisco, CA: Genentech Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21830966">
<a name="21830966"></a>Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. <i>N Engl J Med</i>. 2011;365(6):518-526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/21830966/pubmed" id="21830966" target="_blank">21830966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference">
                  Rock M, Kirchner K, McCubbin M, et al. Aerosol Delivery and Safety of rhDNASE in Young Children With Cystic Fibrosis: A Bronchoscopic Study. <i>Pediatr Pulmonol</i>. 1996;13(Suppl):A268.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11684212">
<a name="11684212"></a>Suri R, Metcalfe C, Lees B, et al, "Comparison of Hypertonic Saline and Alternate-Day or Daily Recombinant Human Deoxyribonuclease in Children With Cystic Fibrosis: A Randomised Trial," <i>Lancet</i>, 2001, 358(9290):1316-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/11684212/pubmed" id="11684212" target="_blank">11684212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15984899">
<a name="15984899"></a>Suri R. The Use of Human Deoxyribonuclease (rhDNase) in the Management of Cystic Fibrosis. <i>BioDrugs</i>. 2005;19(3):135-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/15984899/pubmed" id="15984899" target="_blank">15984899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9787685">
<a name="9787685"></a>Wagener JS, Rock MJ, McCubbin MM, et al. Aerosol Delivery and Safety of Recombinant Human Deoxyribonuclease in Young Children With Cystic Fibrosis: A Bronchoscopic Study. Pulmozyme Pediatric Broncoscopy Study Group. <i>J Pediatr</i>. 1998; 133(4):486-491.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dornase-alfa-drug-information/abstract-text/9787685/pubmed" id="9787685" target="_blank">9787685</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9385 Version 144.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
